Role of gamma-secretase in human umbilical-cord derived mesenchymal stem cell mediated suppression of NK cell cytotoxicity
© Chatterjee et al.; licensee BioMed Central Ltd. 2014
Received: 10 July 2014
Accepted: 24 September 2014
Published: 30 September 2014
Mesenchymal stem cells (MSCs) are increasingly considered to be used as biological immunosuppressants in hematopoietic stem cell transplantation (HSCT). In the early reconstitution phase following HSCT, natural killer (NK) cells represent the major lymphocyte population in peripheral blood and display graft-vs-leukemia (GvL) effects. The functional interactions between NK cells and MSCs have the potential to influence the leukemia relapse rate after HSCT. Until date, MSC-NK cell interaction studies are largely focussed on bone marrow derived (BM)-MSCs. Umbilical cord derived (UC)-MSCs might be an alternative source of therapeutic MSCs. Thus, we studied the interaction of UC-MSCs with unstimulated allogeneic NK cells.
UC-MSCs could potently suppress NK cell cytotoxicity in overnight cultures via soluble factors. The main soluble immunosuppressant was identified as prostaglandin (PG)-E2. Maximal PGE2 release involved IL-1β priming of MSCs after close contact between the NK cells and UC-MSCs. Interestingly, blocking gamma-secretase activation alleviated the immunosuppression by controlling PGE2 production. IL-1 receptor activation and subsequent downstream signalling events were found to require gamma-secretase activity.
Although the role of PGE2 in NK cell-MSC has been reported, the requirement of cell-cell contact for PGE2 induced immunosuppression remained unexplained. Our findings shed light on this puzzling observation and identify new players in the NK cell-MSC crosstalk.
Mesenchymal stem cells (MSCs) are multipotent precursor cells that have the ability to differentiate mainly along chondrogenic, adipogenic and osteogenic lineages . Although MSCs were originally isolated from bone marrow, it is now known that MSCs can be derived from various post-natal tissues like placenta, umbilical cord and cord blood, as well as adult tissues like tooth pulp, skin, adipose tissue, the nervous system and kidney ,. MSCs can be defined as a heterogenous population of plastic-adherent cells with fibroblast-like morphology that express certain markers like CD90, CD73, and CD105, but are negative for surface markers of the hematopoietic lineage such as CD14, CD19, CD34, CD45, and HLA-DR .
MSCs have been reported to mediate profound immunosuppressive effects on T -, B -, NK cells, and dendritic cells . MSCs are referred to as immunoprivileged as they possess a hypo-immunogenic profile due to lack of MHC class II molecules and classical co-stimulatory ligands as well as very low expression of MHC class I . This immunoregulatory capacity together with their inherent non-immunogenicity makes them promising candidates for the use as biological immunosuppressants or tolerance inducers in alloimmune diseases like steroid resistant acute graft-versus-host-disease (GvHD) , organ transplantation or implantation of engineered tissues.
Natural killer (NK) cells are one of the main effectors of innate immunity due to their cytolytic activity against tumour cells and virus infected cells as well as by their ability to secrete various cytokines and chemokines . NK cells comprise the main lymphocyte population in the early reconstitution phase after hematopoietic stem cell transplantation (HSCT) and mediate significant graft-vs-leukemia (GvL) effect , while MSCs are being increasingly used to treat GvHD following HSCT . In therapeutic settings, the interaction of NK cells with MSCs might affect NK cell functions and the transplantation outcome. Clinical intervention to prevent any such adverse outcome of NK-MSC interaction requires precise understanding of the molecular mechanisms utilised by MSCs to suppress NK cells. Some work has been done to characterise the interaction of bone marrow derived MSCs (BM-MSCs) with NK cells -. However, interaction of umbilical cord derived MSCs (UC-MSCs) with NK cells is largely unexplored. Although effective, BM-MSCs are inherently afflicted with the issue of low proliferative potential and only very low numbers of MSCs can be isolated from bone marrow via painful invasive procedures. There is a constant hunt for better sources of MSCs for future clinical cell-based therapies. UC-MSCs have emerged as an ideal candidate owing to their non-invasive isolation procedure, superior proliferative potential and simple accessibility in large quantities . Thus we chose to study UC-MSC-NK cell functional interplay.
This project was aimed at elucidating the underlying molecular mechanisms of UC-MSC mediated immune-modulatory effects on freshly isolated, human NK cells without the presence of any NK cell activating cytokine like IL-15 or IL-2 in the co-culture system. Previous work on BM-MSC-induced suppression of NK cell functions implicated soluble factors like indoleamine 2,3-dioxygenase (IDO), transforming growth factor (TGF)-β and prostaglandin (PG)-E2. PGE2 is the soluble immunosuppressant which is common to all reports till date ,,. However, the suppression of NK activation through PGE2 was reported to be contact dependent . This indicated that the inhibition via PGE2 involved a more complex pathway that is yet to be understood. We also found that the UC-MSCs suppressed NK cell cytotoxicity mainly via PGE2 but the maximal release of PGE2 occurred only in contact cultures. Small amounts of interleukin (IL)-1β present in NK cells preparations were found to act on UC-MSCs to stimulate maximal PGE2 production. Additionally, we show that efficient IL-1 receptor (IL-1R) activation in MSCs require gamma-secretase enzyme activity. These findings further corroborate the recent reports on the identification of IL-1R as a novel gamma-secretase substrate .
Phenotypic analysis and differentiation potential of UC-MSCs
Effect of UC-MSCs on NK cell function and phenotype
Following HSCT, CD56bright NK cell subset is the major NK cell population in peripheral blood ,,. Our study aims to understand the fate of NK cells following MSC co-transfusion in HSCT settings. Therefore, we also specifically analysed the effect of MSCs on CD56bright NK cells. We found that co-culturing with MSCs could significantly suppress K562-induced degranulation (Figure 2B) as well as IL-12 + IL-18 stimulated interferon-γ production by CD56bright NK cells (Additional file 2: Figure S2). The observed suppression of NK cell cytotoxicity could have resulted from an altered expression of NK cells surface receptors which are crucial to NK cell activation. Using flow cytometry-based analysis, we looked for phenotypic changes on NK cells pre-cultured with MSCs compared to NK cells cultured alone. The panel of NK cell receptors analysed included CD16, CD27, CD62L, CD69, CD94, CD158, CD244, CD247, CD335, CD336, CD337, NKG2A, and NKG2D. Interestingly, the expression of all receptors tested was unaffected (Additional file 3: Figure S3) by MSCs, except for NKG2D. UC-MSCs significantly downregulated NKG2D receptor expression on both CD56dim and CD56bright NK cells (Figure 2C,D). We also examined if perforin or granzyme contents of NK cells were altered upon co-culturing with MSCs. Intracellular staining demonstrated that perforin and granzyme contents of NK cells cultured with MSCs were comparable to NK cells cultured alone (Figure 2E,F,G,H, Additional file 4: Figure S4).
Mechanism of MSC-mediated suppression of NK cell cytotoxic functions
Role of gamma-secretase in IL-1 signalling
We observed that UC-MSCs were able to suppress NK cell effector functions in 16 hours of co-culture which is much shorter than the effective co-culture period described by other groups ,. This discrepancy could be possibly explained by different culture conditions. The impairment of NK cell cytotoxicity towards K562 cells probably resulted from reduced degranulation. Interestingly, following co-culture with UC-MSCs, there was preferential downregulation of NKG2D on NK cells while no change was observed in the other activating receptors examined. NKG2D is one of the most prominent activating receptor on the NK cells . The downregulation of NKG2D could be partially responsible for reduced NK cells degranulation towards K562 targets because this cell line expresses NKG2D activating ligand . To understand if soluble factors have any role in the diminution of NK cell cytotoxicity, we compared cell-free supernatants from MSC cultures and NK-MSC contact cultures for their NK cells suppressive ability. It was evident from our experiments that soluble factors present in the media were responsible for the observed immunosuppression. NK-MSC cm was significantly superior to MSC cm in suppressing cytotoxic potential of NK cells indicating a need for a direct contact between the UC-MSCs and NK cells, for the maximal release of the cytotoxicity suppressant.
Soluble factors like TGF-β, kynurenine and PGE2 released by enzymatic action of COX-2 have been reported to be involved in inhibition of immune cell functions by BM-MSCs ,,. In our assays, antibody-mediated blocking of TGF-β and pharmacological inhibition of IDO via 1-methyl-tryptophan (MT) did not result in any restoration of the degranulative potential of NK cells. These differences could result from the use of unstimulated freshly isolated NK cells in our experiments. It is known that IDO is induced by IFN-γ in MSC , and freshly isolated NK cells did not produce considerable amount of IFN-γ (data not shown). We found that COX-2 was constitutively expressed in UC-MSCs. Blocking COX-2 resulted in significant restoration of NK cell degranulation suggesting that the soluble cytotoxicity suppressant is PGE2. IL-1β released by NK cells was measured to be in the range of 70-200 pg/ml. In a murine model of ulcerative colitis, IL-1β pre-treated MSCs were found to exhibit significantly higher therapeutic efficacy than untreated MSCs . IL-1β is known to be a potent inducer of COX-2. Hence we neutralised IL-1β in our MSC-NK cell co-cultures and observed that blocking IL-1β indeed resulted in a decrease in COX-2 upregulation.
The induction of COX-2 is dependent on IL-1β release from NK cells. Hence, IL-1β produced by NK cells in transwell co-cultures should also induce COX-2 and PGE2 production. However, no suppression was observed in transwell co-cultures. This can possibly be explained by the low levels of IL-1β produced by NK cells, making direct cell-cell contact a pre-requisite for attaining effective concentrations for bioactivity. In transwell co-cultures, the low IL-1β concentrations appear insufficient to upregulate COX-2 in MSCs. It is important to note that our co-culture duration is just 16 hours. In conditioned media collected from NK cultures (NK cm) after 16 hours, IL-1β has probably reached effective concentrations as implicated by COX-2 upregulation in MSCs exposed to NK cm.
Previous work has demonstrated that gamma-secretase acts on IL-1R and controls the downstream signalling following receptor activation by ligand binding . We hypothesized that the IL-1R signalling in MSCs could also be gamma-secretase dependent. We inhibited gamma-secretase enzyme activity using pharmacological inhibitors or siRNA-mediated knockdown. We found that the inhibition of gamma-secretase significantly reduced COX-2 upregulation in MSCs in response to IL-1R activation by IL-1β. We could also demonstrate that gamma-secretase inhibition also affected JNK phosphorylation down-stream of IL-1R activation. Therefore, we could demonstrate that IL-1R signalling in MSCs was dependent on gamma-secretase activity. This dependence was also mirrored in the drastic mitigation of PGE2 release under conditions of gamma-secretase inhibition. Finally, pharmacological inhibition of gamma-secretase during NK cell-MSC co-cultures showed significant restoration of NK cell degranulation.
Use of MSCs for cell therapy is on the rise, and BM-MSCs have been shown to be advantageous for the treatment and prevention of GvHD as well as facilitation of engraftment following HSCT in several clinical trials . The mechanistic insights obtained from in-vitro studies indicate that the anti-inflammatory effects of MSCs, that ameliorate complications following HSCT, stem from suppression of aberrant T-cell proliferation . Following HSCT, the first lymphocyte population to reconstitute are NK cells, which contribute to improved engraftment, reduced rates of leukemia relapse  and decreased GvHD. MSCs co-administered with HSC to suppress T-cells are also likely to suppress NK cell functions, thereby eliminating their beneficial effects.
We found that UC-MSCs indeed suppress NK cell cytotoxicity in overnight contact cultures. The suppression is mediated by the soluble suppressant PGE2. However, the maximal release of PGE2 required a cross-talk between NK cells and MSCs involving IL-1β/IL-1R signalling. The low IL-1β levels are probably more effective within the immunological synapse formed in contact cultures. This could explain the contact dependence of observed suppression. We also show that the IL-1R signalling is dependent on gamma-secretase enzyme activity. Finally, pharmacological inhibition of gamma-secretase significantly alleviated MSC-induced suppression. We need to further investigate if these immunosuppressive mechanisms also apply to MSCs derived from other sources. Identification of common molecular pathways utilised by MSCs, irrespective of the source, could have significant clinical implications, especially in case of HSCT.
Materials and methods
Isolation and culture of UC-MSCs
This study was approved on 26th February, 2009 by the Institutional Review Board (Project No. 3037) in an extended permission # 443. After obtaining written consent, MSCs were isolated from at least four different human umbilical cords obtained from full-term infants (38-40 weeks) by explant culture, expanded and cryopreserved until the start of the experiment as described elsewhere ,. μMEM supplemented with 10% human serum and 50 g/ml streptomycin, 50U/ml penicillin, 1mM glutamine and 0.5mM sodium pyruvate (Biochrom, Berlin, Germany) was used to culture UC-MSCs for all subsequent experiments.
Isolation of peripheral blood mononuclear cells (PBMC) and NK cells
Heparinised blood samples were obtained from healthy consenting donors and diluted with an equal volume of phosphate buffered saline (PBS). PBMC were separated by centrifugation over a ficoll-hypaque gradient and stained with anti-CD56 and CD3 antibodies. NK cells were sorted using MoFlo Cell Sorter (Beckman Coulter) at the MHH sorting facility. NK cells were defined as CD56+CD3− lymphocytes.
Monoclonal antibodies (mAbs)
The anti-human mAbs have been used: CD3 PE (from Beckman Coulter), CD3 PerCP, CD11b PE, CD14 APC, CD56 PE, CD56 APC, CD73 PE, CD107a FITC, Granzyme A FITC, Perforin FITC, pJNK PE (from BD Biosciences), HLA-DR FITC (Dako), CD44 FITC, CD105 FITC, Granzyme B PE, Granzyme K Alexa647 (Immunotools), CD90 APC, COX2 FITC (Cayman chemicals). Each flow cytometric analysis was controlled with isotype-matched mAbs. All flow cytometry-based experiments were performed on FACS Calibur using Cell-Quest Pro Software. Offline data analysis was done on Summit 5.1 software.
UC-MSCs were seeded in 24- or 48-well plates and allowed to adhere. After 24 hours, freshly isolated, FACS-sorted NK cells from unrelated donors were added at a MSC:NK-ratio of 1:10. Following 16 hours of co-culture, the NK cells were removed from the adherent MSCs by pipetting for phenotyping or were tested for cytokine producing ability by intracellular staining or for cytotoxic potential against K562 leukemic cells using CD107a degranulation or chromium release assay. NK cells cultured without MSCs were used as controls. Cell-free supernatants from the NK-MSC co-cultures or MSC cultures were frozen for further analysis as MSC-NK-conditioned medium (NK-MSC cm) or MSC conditioned media (MSC cm), respectively. For determining the influence of conditioned media, NK cells from the unrelated donors were cultured for 16 hours in the cell-free supernatants generated as mentioned above. To determine the role of gamma-secretase activation, N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) (Sigma-Aldrich, Germany), a gamma-secretase inhibitor, was added to the co-cultures at 6 μM or 10 μM concentrations. DMSO was used as vehicle control. 5 μM NS-398 was added to the co-cultures to block the action of cyclooxygenase (COX)-2. IL-1β neutralising antibody or the matched isotype control antibody was added to the co-cultures at a concentration of 10 ng/ml.
Detection of intracellular proteins
For detection of perforins and granzymes, after surface staining, cells were fixed with 4% paraformaldehyde (Merck) for 10 min. Subsequently, the cells were perforated in 0.1% saponin buffer (PBS supplemented with 0.1% Saponin (Riedel-de-Haën) and 0.01M HEPES (Roth) and fluorochrome-tagged monoclonal antibodies (mAbs) were added. After 30 minutes of incubation and three washes, cells were analysed by flow cytometry.
For detection of COX-2, the MSCs were detached by Accutase (Life technologies) treatment at 37°C for 5 min and fixed with 4% paraformaldehyde followed by 30 minute incubation with anti-COX-2 mAb in saponin buffer. The cells were then washed and analysed by flow cytometry.
For detection of pJNK, MSCs were stimulated with IL-1β for 40 minutes and washed once with PBS. Detachment of MSCs using Accutase was immediately followed by fixation using 1X BD Lyse/Fix Buffer. The permeabilisation and intracellular staining for pJNK was performed according to manufacturer's protocol.
CD107a degranulation assay
NK cells cultured with or without MSCs were incubated with K562 target cells in presence of anti-CD107a mAb at an Effector:Target (E:T) ratio of 10:1. Monensin (BD Biosciences) was added after 1 hour at a final concentration of 6 g/ml and the incubation was continued for 3 hours. The cells were then analysed for the surface-expression of CD107a by flow cytometry.
Cytotoxicity assay against K562 target cells
Cytotoxicity of NK cells, cultured under different conditions e.g in presence/absence of MSCs or in the presence/absence of conditioned media, was determined by 4 hour chromium release assay against K562 target cells following the protocol as described elsewhere . Briefly, K562 cells were labelled with radioactive 51Cr by incubating the cells with 3 MBq Na51CrO4 for 1h at 37°C. The cells were washed twice and plated in triplicates in V-bottom 96-well plates. Effector: Target ratios of 20:1, 10:1, 5:1 and 2.5:1 were used. NK cell mediated lysis of targets results in the release of 51Cr into the supernatant. Following the 4 hour incubation, the plates were centrifuged. 25 μl cell-free supernatant was collected from each well, and the 51Cr release was measured by a gamma counter. Lytic units (LU20/107 cells) of the assays were calculated according to the methods established by Bryant et al..
Cytokine bead array
The amount of IL-1β present in the culture supernatants of NK cells was measured using the cytometric bead array kit (BD Biosciences) in combination with human IL-1β Flex set according to the manufacturer's protocol. Briefly, fluorescently labelled beads (bead position B4) were mixed with known standards or test samples followed by incubation with PE-conjugated detection antibodies. The samples were washed, measured on FACS Canto II and analysed using the BD CBA analysis software.
PGE2 was measured in culture supernatants by competitive enzyme-linked immunosorbent assay (ELISA) technique using a commercially available ELISA kit (Enzo Life Sciences), according to the manufacturer's protocol. Concentrations were calculated by comparison with known PGE2 standards using a 5 parameter logistic curve fitting program.
The following small interfering RNA (siRNA) were obtained from Dharmacon, Thermo Scientific: ON-TARGETplus Non-targeting Control Pool (D-001810-10-05), ON-TARGETplus PSEN1; Set of 4 (LQ-004998-00-0002). The four individual PSEN1 targeting siRNAs were mixed (i.e. 37.5 pmol each) before use. Transfection with siRNAs was performed using the Neon transfection system (Invitrogen) at 1350 V, 10 ms, 4 pulses; according to the manufacturer's instructions. siRNAs were microporated at the concentration of 150 pmol into 8×104 cells.
Total RNA was isolated from siRNA-treated UC-MSCs using RNAeasy Micro Kit (Qiagen), according to manufacturer's protocol. cDNA was prepared using a commercially available reverse transcription kit (Applied Biosystems; Cat. No: 4368814). Expression of PSEN-1 mRNA relative to β-actin was analyzed using semi-quantitative PCR. All experiments were performed in triplicates. Fold change in PSEN-1 mRNA expression was calculated using the 2-ΔΔCT method. The following primers were used: PSEN-1 primer pair (SantaCruz Biotechnology, Inc.; Cat. No: sc-36312-PR) and β-actin quantitect primers (Qiagen.; Cat. No: QT00095431).
Paired two-tailed t-tests or ANOVA with Bonferroni post-test were performed using GRAPHPAD PRISM V5.00 Software. Levels of significance are shown as p-values (* p < 0.05, ** p < 0.01, *** p < 0.001). Bar graphs represent mean +/- standard deviation (SD).
DC, NM, DMT, GB, HZL, TH, RH and RJ performed experiments; CvK contributed the umbilical cords, TH and CK contributed vital reagents and discussed the data, DC, NM, HZL and RJ analyzed the results and made the figures; DC, NM, CK, RES, and RJ designed the research; DC wrote the paper. All authors read and approved the final manuscript.
The authors would like to extend our sincere appreciation to the Cell Sorting Core Facility, MHH for their support. We would like to thank Sabine Buyny for her assistance with the 51Cr release assays and Katja Kniesch for her help.
This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG): SFB738/A5, Hannover Biomedical Research School (HBRS), REBIRTH Cluster of Excellence, Nieders°Chsische Krebsgesellschaft e.V.
- Pittenger MF: Multilineage potential of adult human mesenchymal stem cells. Science. 1999, 284: 143-147. 10.1126/science.284.5411.143.PubMedView ArticleGoogle Scholar
- Hass R, Kasper C, Böhm S, Jacobs R: Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal. 2011, 9: 12-10.1186/1478-811X-9-12.PubMedPubMed CentralView ArticleGoogle Scholar
- Majore I, Moretti P, Stahl F, Hass R, Kasper C: Growth and differentiation properties of mesenchymal stromal cell populations derived from whole human umbilical cord. Stem Cell Rev. 2011, 7: 17-31. 10.1007/s12015-010-9165-y.PubMedView ArticleGoogle Scholar
- Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006, 8: 315-317. 10.1080/14653240600855905.PubMedView ArticleGoogle Scholar
- Uccelli A, Pistoia V, Moretta L: Mesenchymal stem cells: a new strategy for immunosuppression?. Trends Immunol. 2007, 28: 219-226. 10.1016/j.it.2007.03.001.PubMedView ArticleGoogle Scholar
- Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC: Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003, 75: 389-397. 10.1097/01.TP.0000045055.63901.A9.PubMedView ArticleGoogle Scholar
- Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringdén O: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008, 371: 1579-1586. 10.1016/S0140-6736(08)60690-X.PubMedView ArticleGoogle Scholar
- Vivier E, Raulet DH, Moretta A, Caligiuri M, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S: Innate or adaptive immunity? The example of natural killer cells. Science. 2011, 331: 44-49. 10.1126/science.1198687.PubMedPubMed CentralView ArticleGoogle Scholar
- Jacobs R, Stoll M, Stratmann G, Leo R, Link H, Schmidt RE: CD16°CD56+ natural killer cells after bone marrow transplantation. Blood. 1992, 79: 3239-3244.PubMedGoogle Scholar
- Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002, 295: 2097-2100. 10.1126/science.1068440.PubMedView ArticleGoogle Scholar
- Vianello F, Dazzi F: Mesenchymal stem cells for graft-versus-host disease: a double edged sword?. Leukemia. 2008, 22: 463-465. 10.1038/leu.2008.25.PubMedView ArticleGoogle Scholar
- Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M: Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 2006, 24: 74-85. 10.1634/stemcells.2004-0359.PubMedView ArticleGoogle Scholar
- Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L: Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008, 111: 1327-1333. 10.1182/blood-2007-02-074997.PubMedView ArticleGoogle Scholar
- Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L: Mesenchymal stem cell – natural killer cell interactions : evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2 – induced NK-cell proliferation. Immunobiology. 2006, 107: 1484-1490.Google Scholar
- Wu K-H, Chan C-K, Tsai C, Chang Y-H, Sieber M, Chiu T-H, Ho M, Peng C-T, Wu H-P, Huang J-L: Effective treatment of severe steroid-resistant acute graft-versus-host disease with umbilical cord-derived mesenchymal stem cells. Transplantation. 2011, 91: 1412-1416. 10.1097/TP.0b013e31821aba18.PubMedView ArticleGoogle Scholar
- Noone C, Kihm A, English K, O’Dea S, Mahon BP: IFN-γ stimulated human umbilical-tissue-derived cells potently suppress NK activation and resist NK-mediated cytotoxicity in vitro. Stem Cells Dev. 2013, 22: 3003-3014. 10.1089/scd.2013.0028.PubMedPubMed CentralView ArticleGoogle Scholar
- Elzinga BM, Twomey C, Powell JC, Harte F, McCarthy JV: Interleukin-1 receptor type 1 is a substrate for gamma-secretase-dependent regulated intramembrane proteolysis. J Biol Chem. 2009, 284: 1394-1409. 10.1074/jbc.M803108200.PubMedView ArticleGoogle Scholar
- Dulphy N, Haas P, Busson M, Belhadj S, Peffault de Latour R, Robin M, Carmagnat M, Loiseau P, Tamouza R, Scieux C, Rabian C, Di Santo JP, Charron D, Janin A, Socie G, Toubert A: An unusual CD56brightCD16low NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. J Immunol. 2008, 181: 2227-2237. 10.4049/jimmunol.181.3.2227.PubMedView ArticleGoogle Scholar
- Nguyen S, Dhedin N, Vernant J, Kuentz M, Al JA, Rouas-freiss N, Carosella ED, Boudifa A, Debre P, Vieillard V, Nkga CD: NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations/: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood. 2005, 105: 4135-4142. 10.1182/blood-2004-10-4113.PubMedView ArticleGoogle Scholar
- Small DH, Klaver DW, Foa L: Presenilins and the gamma-secretase: still a complex problem. Mol Brain. 2010, 3: 7-10.1186/1756-6606-3-7.PubMedPubMed CentralView ArticleGoogle Scholar
- Haapasalo A, Kovacs D: The many substrates of presenilin/γ-secretase. J Alzheimers Dis. 2012, 25: 3-28.Google Scholar
- Raulet DH: Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003, 3: 781-790. 10.1038/nri1199.PubMedView ArticleGoogle Scholar
- Li C, Ge B, Nicotra M, Stern JNH, Kopcow HD, Chen X, Strominger JL: JNK MAP kinase activation is required for MTOC and granule polarization in NKG2D-mediated NK cell cytotoxicity. Proc Natl Acad Sci U S A. 2008, 105: 3017-3022. 10.1073/pnas.0712310105.PubMedPubMed CentralView ArticleGoogle Scholar
- Aggarwal S, Pittenger MF: Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005, 105: 1815-1822. 10.1182/blood-2004-04-1559.PubMedView ArticleGoogle Scholar
- Meisel R, Zibert A, Laryea M, Göbel U, Däubener W, Dilloo D: Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004, 103: 4619-4621. 10.1182/blood-2003-11-3909.PubMedView ArticleGoogle Scholar
- Fan H, Zhao G, Liu L, Liu F, Gong W, Liu X, Yang L, Wang J, Hou Y: Pre-treatment with IL-1β enhances the efficacy of MSC transplantation in DSS-induced colitis. Cell Mol Immunol. 2012, 9: 473-481. 10.1038/cmi.2012.40.PubMedPubMed CentralView ArticleGoogle Scholar
- Kim E-J, Kim N, Cho S-G: The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation. Exp Mol Med. 2013, 45: e2-10.1038/emm.2013.2.PubMedPubMed CentralView ArticleGoogle Scholar
- Shilling HG, Guethlein LA, Cheng NW, Gardiner CM, Rodriguez R, Tyan D, Parham P: Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype. J Immunol. 2002, 168: 2307-2315. 10.4049/jimmunol.168.5.2307.PubMedView ArticleGoogle Scholar
- Hatlapatka T, Moretti P, Lavrentieva A, Hass R, Marquardt N, Jacobs R, Kasper C: Optimization of culture conditions for the expansion of umbilical cord-derived mesenchymal stem or stromal cell-like cells using xeno-free culture conditions. Tissue Eng Part C Methods. 2011, 17: 485-493. 10.1089/ten.tec.2010.0406.PubMedView ArticleGoogle Scholar
- Schmidt RE, MacDermott RP, Bartley GT, Bertovich M, Amato DA, Austen KF, Schlossman SF, Stevens RL: Specific release of proteoglycans from human natural killer cells during target lysis. Nature. 1985, 318: 289-10.1038/318289a0.PubMedView ArticleGoogle Scholar
- Bryant J, Day R, Whiteside TL, Herberman RB: Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Immunol Methods. 1992, 146: 91-103. 10.1016/0022-1759(92)90052-U.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.